Thin
1 / 2
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy.
Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.
Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.
Retatrutide is a novel multi-agonist peptide that simultaneously targets three receptors: GLP-1, GIP, and glucagon receptors.
It is designed to enhance glucose regulation, promote significant weight loss, and support overall metabolic health.
Retatrutide is currently under active investigation in clinical and preclinical research primarily for the management of obesity and type 2 diabetes mellitus (T2DM).
No, Retatrutide is currently an investigational peptide in Phase 3 clinical trials and is not yet approved by the FDA for clinical use.
In clinical trials, Retatrutide is administered as a once-weekly subcutaneous injection.
Trial protocols have explored dosages ranging from 1 mg up to 12 mg, which are often titrated over multiple 4-week intervals to optimize efficacy while maintaining tolerability.
